InvestorsHub Logo
Followers 42
Posts 5813
Boards Moderated 0
Alias Born 10/04/2000

Re: satelliteguy post# 1717

Thursday, 09/10/2009 7:57:43 AM

Thursday, September 10, 2009 7:57:43 AM

Post# of 5675
CTD Holdings Announces Second Quarter Results

HIGH SPRINGS, FL--(Marketwire - September 10, 2009) - CTD Holdings, Inc. (OTCBB: CTDH) (FRANKFURT: CDJ) announced today its second quarter results of operations.

Net Operating Loss decreased 36.7% and product sales increased 6.9% to almost $245,000 for the first six months of 2009 compared to the same period in 2008.

"Although profit and loss have not been emphasized by management in the past because the dollar amounts were always small, it's nice to see both going in the right direction. Third quarter sales have gotten off to a great start already," stated Rick Strattan, Chairman/CEO of the company. "We should reduce expenses even more in the third quarter and going forward by eliminating $13,500 per month of non-cash expenses by the elimination of stock for salary to me and George Fails, the new President."

"On the revenue side, the Cyclo™ trials are going well and the list of potential clients for VGP is getting large enough that one or two could well become a reality in the third quarter, or certainly by the fourth quarter," continued Mr. Strattan.

"Finally," Mr. Strattan added, "as a result of the confidence in our new business model, we are going to get more aggressive in the repurchase of our shares on the open market."

About CTD Holdings, Inc.

The company is the one-stop shop, business-to-business facilitator of commercial and research applications of Cyclodextrins. With its branded Trappsol®, Aquaplex® and Cyclo™ product offerings, CTDH scientists coordinate the development of commercial products for use in the pharmaceuticals, foods, hazardous waste treatment, and cosmetics industries, which endeavor to put non water-soluble ingredients into water-based formulations. More recently CTDH has worked, in an advisory capacity, on the benefits and application of Cyclodextrins as a treatment for Neimann Pick C disease, a debilitating childhood disease often called Childhood Alzheimer's. CTDH was founded in 1990 as a Florida corporation and became a public company in 1994. Additional information on the Company can be found on the Company's website: www.cyclodex.com

This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements. CTDH complies with the regulations and time lines mandated by the SEC in the filing of its financial reports; these filings also contain forward-looking statements. The above forward-looking statements are made as of the date above; CTD Holdings, Inc accepts no specific responsibility for updating such statements.

"But what is liberty without wisdom, and without virtue? It is the greatest of all possible evils; for it is folly, vice, and madness, without tuition or restraint.” Edmund Burke

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYTH News